177Lu-PSMA-RLT of metastatic castration-resistant prostate cancer: limitations and improvements

被引：0
作者：
Jianpeng Cao
Yue Chen
Mei Hu
Wei Zhang
机构：
[1] The Affiliated Hospital of Southwest Medical University,Department of Nuclear Medicine
[2] The Affiliated Hospital of Southwest Medical University,Academician (Expert) Workstation of Sichuan Province
[3] The Affiliated Hospital of Southwest Medical University,Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province
[4] Sichuan Academy of Medical Sciences/Sichuan Provincial People’s Hospital,undefined
来源：
Annals of Nuclear Medicine | 2021年 / 35卷
关键词：
Lu; Prostate-specific membrane antigen (PSMA); Radioligand therapy (RLT); mCRPC; Limitations;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The prevalence of metastatic castration-resistant prostate cancer (mCRPC) is increasing, and its prognosis is often poor. As a highly expressed target in mCRPC, prostate-specific membrane antigen (PSMA) is very attractive for its diagnosis and treatment. When the efficacy of chemical therapy is limited, radioligand therapy (RLT)-based on Lutetium-177 (177Lu)-PSMA has received more research as an emerging treatment. To date, most published related studies have proven this method is effective and safe. However, about 1/3 of mCRPC patients have not benefited from 177Lu-PSMA-RLT. The underlying mechanism of this phenomenon remains unclear. So based on the comprehensive research in recent years, this article proposes the possible reasons, including tumor lesions, PSMA heterogeneity, differences in DNA repair defects, and accelerated repopulation. Combining with the existing experience to give suggestions to improve the treatment efficacy, benefit more mCRPC patients.
引用
收藏
页码：861 / 870
页数：9
相关论文
共 555 条
  • [1] Sung H(2021)Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 71 209-249
  • [2] Ferlay J(2017)Enzalutamide in men with chemotherapy-naïve metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study Eur Urol 71 151-154
  • [3] Siegel RL(2015)Treating patients with metastatic castration resistant prostate cancer: a comprehensive review of available therapies J Urol 194 1537-1547
  • [4] Laversanne M(2020)Prostate-specific membrane antigen (PSMA)-ligand positron emission tomography and radioligand therapy (RLT) of prostate cancer Jpn J Clin Oncol 50 349-356
  • [5] Soerjomataram I(2014)PSMA, EpCAM, VEGF and GRPR as imaging targets in locally recurrent prostate cancer after radiotherapy Int J Mol Sci 15 6046-6061
  • [6] Jemal A(2017)Ga-PSMA-11 PET imaging of response to androgen receptor inhibition: first human experience J Nucl Med 58 81-84
  • [7] Beer TM(2015)Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer J Nucl Med 56 914-920
  • [8] Armstrong AJ(2015)Ga- and J Nucl Med 56 1169-1176
  • [9] Rathkopf D(2016)Lu-labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies J Nucl Med 57 97S-104S
  • [10] Loriot Y(2017)PSMA-based radioligand therapy for metastatic castration-resistant prostate cancer: the bad Berka experience since 2013 Eur J Nucl Med Mol Imaging 44 1448-1454
12345678910